Orris

find out the hypothesis and the research gap of this study

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

find out the hypothesis and the research gap of this study

Reading File
Running Command

cd /tmp/workspace/attachments/78808871-c298-41db-b5a2-6b018f883440/ && ls -la && python3 -c " import pdfplumber with pdfplumber.open('article 1.pdf') as pdf: print('Pages:', len(pdf.pages)) for i, page in enumerate(pdf.pages[:6]): text = page.extract_text() print(f'--- PAGE {i+1} ---') print(text) "

Hypothesis and Research Gap

Study: Kunitsu et al., "NSAID-Induced Acute Kidney Injury Risk in Patients on Renin-Angiotensin System Inhibitors and Diuretics: Nationwide Cohort Study" (J Pharm Health Care Sci, 2025)

Research Gap

Prior literature had established that "Triple Whammy" (TW) therapy - the combination of renin-angiotensin system inhibitors (RASIs) + diuretics + NSAIDs - raises acute kidney injury (AKI) risk, but several important gaps remained unresolved:
  1. No consensus on whether NSAID type matters. It was unclear whether COX-2 selective NSAIDs (sCOX2-i, e.g., celecoxib) carry a different AKI risk than nonselective NSAIDs (nsCOX-i), since:
    • sCOX2-i have a lower impact on blood pressure and were thought to have a reduced risk of renal events.
    • However, COX-2 is also expressed in the kidney, and some studies suggested sCOX2-i should be avoided in CKD/heart failure patients just like nsCOX-i.
    • Lapi et al. previously compared AKI risk by NSAID half-life (>12h vs not) and found no significant difference, but COX-2 selectivity specifically had not been resolved.
  2. Incidence rates of AKI during TW were inconsistent across studies. Camin et al. reported an incidence rate of 8.82/1,000 person-years, but defined TW only at the time of drug initiation without tracking whether the three-drug combination was actually sustained (continuity of TW use was unknown) - making true incidence during ongoing TW exposure unclear.
  3. Most prior AKI-risk analyses used nested case-control designs, which are suited to long-term risk factors but not ideal for capturing the short-term triggering effect of adding an NSAID. A complementary case-crossover approach (better suited for short-term/rare acute events) had not been applied to this specific question of NSAID-type-based risk in TW.
In short: no study had yet examined AKI incidence during sustained TW therapy while simultaneously stratifying the risk by NSAID composition and COX-2 selectivity, using both a long-term incidence design and a short-term case-crossover design together. The authors state this explicitly: "To the best of our knowledge, this study is the first to report AKI incidence during TW persistence and to classify risk based on NSAID composition and COX-2 selectivity."

Hypothesis

The study's underlying hypothesis (framed from its stated aim and background) is:
Adding NSAIDs to a regimen of RASIs + diuretics increases the risk of AKI, and this risk may differ depending on the type of NSAID used - specifically, COX-2 selective NSAIDs are hypothesized to carry a lower AKI risk than nonselective NSAIDs, given their more favorable renal/blood-pressure profile reported in earlier literature.
This is operationalized as two testable components:
  • H1 (main effect): NSAID addition to RASI + diuretic therapy significantly increases AKI incidence/risk compared to RASI + diuretic use alone.
  • H2 (differential effect): COX-2 selective NSAIDs are associated with lower AKI risk than nonselective COX inhibitors.

What They Actually Found (for context)

  • H1 was supported: incidence rate ratio of 2.08 (95% CI: 1.58-2.74) for TW vs. RASI+diuretics alone; case-crossover adjusted OR of 1.44 (95% CI: 1.17-1.78) for NSAID use before AKI onset.
  • H2 was not supported: no significant difference between sCOX2-i and nsCOX-i (relative OR 0.99, 95% CI: 0.66-1.50), aOR for nsCOX-i 1.43 (95% CI: 1.13-1.80) and for sCOX2-i 1.42 (95% CI: 1.01-2.00) - both elevated similarly, contradicting the hypothesis that COX-2 selectivity would be protective. This directly filled the identified research gap by showing NSAID type/COX-2 selectivity does not meaningfully alter AKI risk within TW therapy, supporting the conclusion that all NSAIDs should be monitored carefully regardless of type.
This is a shared conversation. Sign in to Orris to start your own chat.